A prospective randomized, double-blind placebo-controlled study to evaluate the effectiveness of neuroprotective therapy using functional brain MRI in patients with post-covid chronic fatigue syndrome. — ME/CFS Atlas
E1 ReplicatedPreliminaryPEM not requiredRCTPeer-reviewedReviewed
Standard · 3 min
A prospective randomized, double-blind placebo-controlled study to evaluate the effectiveness of neuroprotective therapy using functional brain MRI in patients with post-covid chronic fatigue syndrome.
Tanashyan, M, Morozova, S, Raskurazhev, A et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023 · DOI
Quick Summary
Researchers tested whether a drug called CCSA (a compound containing succinate acid) could help people with post-COVID fatigue and brain fog. They used advanced brain imaging scans to measure changes in brain activity before and after treatment. The CCSA group showed greater improvement in fatigue symptoms and thinking skills compared to the placebo group.
Why It Matters
Post-COVID fatigue shares phenotypic overlap with ME/CFS, and this study provides objective neuroimaging evidence linking symptom improvement to measurable changes in brain function. Understanding neuroprotective mechanisms in post-COVID populations may inform therapeutic approaches applicable to ME/CFS, where cognitive dysfunction and fatigue are core features.
Observed Findings
CCSA-treated patients showed greater reduction in fatigue severity on MFI-20 scale (−20 points vs −12 points in placebo, p=0.043)
Cognitive scores on MoCA improved more in CCSA group (+2 points vs +1 point, p<0.05)
Task-based fMRI and resting-state fMRI showed changes in brain activation patterns correlating with clinical improvement in CCSA group
No adverse events or safety concerns reported for CCSA treatment
Both groups completed pre- and post-treatment assessment with matched demographic characteristics
Inferred Conclusions
CCSA demonstrates potential neuroprotective efficacy across multiple symptom domains (fatigue and cognitive impairment) in post-COVID syndrome
Functional neuroimaging changes correlate with clinical symptom improvement following CCSA therapy
High-field fMRI can serve as an objective biomarker for treatment response monitoring in post-COVID asthenic syndrome
Remaining Questions
What is the optimal dose and duration of CCSA treatment, and does efficacy persist beyond the treatment period?
Does CCSA effectiveness extend to primary ME/CFS or other post-viral fatigue syndromes, or is it specific to post-COVID presentations?
What This Study Does Not Prove
This study does not prove CCSA is effective for ME/CFS or primary post-viral fatigue broadly—findings are specific to post-COVID asthenic syndrome in this sample. Small sample size (n=15 per group) limits generalizability. The study demonstrates correlation between neuroimaging changes and clinical improvement but does not establish whether brain imaging changes are mechanistically responsible for symptom relief or merely associated with it.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
What are the mechanistic pathways by which CCSA exerts neuroprotection—does it improve mitochondrial function, reduce neuroinflammation, or restore specific neural networks?
What is the long-term safety and tolerability profile of CCSA with extended treatment duration?